T1	PROC 44 75	Estudio maestro de continuación
T2	LIVB 79 88	pacientes
#1	AnnotatorNotes T2	C0030705; Patients; Patient or Disabled Group
T3	PROC 113 133	estudio en oncología
T4	CHEM 145 155	Durvalumab
#2	AnnotatorNotes T4	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	PROC 184 215	Estudio maestro de continuación
T6	LIVB 219 228	pacientes
#3	AnnotatorNotes T6	C0030705; Patients; Patient or Disabled Group
T7	PROC 253 273	estudio en oncología
T8	CHEM 281 291	Durvalumab
#4	AnnotatorNotes T8	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	LIVB 301 313	investigador
#5	AnnotatorNotes T9	C0035173; Research Personnel; Professional or Occupational Group
T10	PROC 363 387	continuar el tratamiento
T11	DISO 409 461	Carcinoma urotelial y no urotelial de vías urinarias
T12	Neg_cue 431 433	no
T13	Negated 434 443	urotelial
T14	Date 462 478	posquimioterapia
T15	LIVB 479 488	Pacientes
#6	AnnotatorNotes T15	C0030705; Patients; Patient or Disabled Group
T17	DISO 510 546	cáncer de pulmón de células pequeñas
#7	AnnotatorNotes T17	C0149925; Small cell carcinoma of lung; Neoplastic Process
T18	DISO 548 552	CPCP
#8	AnnotatorNotes T18	C0149925; Small cell carcinoma of lung; Neoplastic Process
T19	DISO 558 568	enfermedad
#9	AnnotatorNotes T19	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T20	DISO 587 649	Cáncer de pulmón de células no pequeñas avanzado o metastásico
#10	AnnotatorNotes T20	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T21	Neg_cue 615 617	no
T22	Negated 618 626	pequeñas
T24	LIVB 653 662	pacientes
#12	AnnotatorNotes T24	C0030705; Patients; Patient or Disabled Group
T25	Neg_cue 663 666	sin
T26	PROC 667 678	tratamiento
#13	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	Negated 667 678	tratamiento
T28	CHEM 690 735	receptor del factor de crecimiento epidérmico
#14	AnnotatorNotes T28	C1739039; EGFR protein, human; Amino Acid, Peptide, or Protein · Receptor
T29	Negated 690 735	receptor del factor de crecimiento epidérmico
T30	CHEM 737 741	EGFR
#15	AnnotatorNotes T30	C1739039; EGFR protein, human; Amino Acid, Peptide, or Protein · Receptor
T31	Negated 737 741	EGFR
T32	DISO 745 762	patología tumoral
T33	LIVB 766 770	cepa
T34	CHEM 784 813	quinasa de linfoma anaplásico
T35	CHEM 815 818	ALK
#16	AnnotatorNotes T35	C1663627; ALK protein, human; Amino Acid, Peptide, or Protein · Enzyme · Receptor
T36	DISO 821 894	Cáncer de pulmón de células no pequeñas no resecable, localmente avanzado
#17	AnnotatorNotes T36	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T37	Neg_cue 849 851	no
T38	Negated 852 860	pequeñas
T39	Neg_cue 861 863	no
T40	Negated 864 873	resecable
T41	DISO 951 957	cáncer
#18	AnnotatorNotes T41	C0006826; Malignant Neoplasms; Neoplastic Process
T42	PROC 1037 1067	ICF escrito, firmado y fechado
T43	LIVB 1076 1084	paciente
#19	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	Date 1093 1104	actualmente
T45	LIVB 1151 1163	investigador
#20	AnnotatorNotes T45	C0035173; Research Personnel; Professional or Occupational Group
T46	PROC 1169 1189	tratamiento contínuo
T47	CHEM 1235 1250	compuesto de AZ
T48	LIVB 1327 1335	paciente
#21	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T49	PROC 1367 1378	tratamiento
#22	AnnotatorNotes T49	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T51	DISO 1458 1467	Toxicidad
#24	AnnotatorNotes T51	C0600688; Toxic effect; Injury or Poisoning
T52	Date 1468 1476	en curso
T53	Neg_cue 1478 1480	no
T54	Negated 1481 1489	resuelta
T55	PROC 1529 1557	interrupción del tratamiento
T56	Date 1618 1629	Actualmente
T57	Contraindicated 1638 1653	tratamiento con
T58	PROC 1638 1649	tratamiento
#25	AnnotatorNotes T58	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T59	CHEM 1660 1671	medicamento
#26	AnnotatorNotes T59	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T60	Contraindicated 1660 1671	medicamento
T61	PROC 1744 1764	investigación médica
T62	Neg_cue 1769 1771	no
T63	Negated 1785 1820	científica o médicamente compatible
T64	PROC 1843 1855	Interrupción
T65	DISO 1898 1907	toxicidad
#27	AnnotatorNotes T65	C0600688; Toxic effect; Injury or Poisoning
T66	DISO 1910 1937	progresión de la enfermedad
#28	AnnotatorNotes T66	C0242656; Disease Progression; Pathologic Function
T67	CHEM 1958 1970	medicamentos
#29	AnnotatorNotes T67	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T68	Neg_cue 1998 2001	sin
T69	Negated 2002 2007	costo
T70	LIVB 2016 2024	paciente
#30	AnnotatorNotes T70	C0030705; Patients; Patient or Disabled Group
T72	DISO 2166 2174	COVID-19
#32	AnnotatorNotes T72	C5203670; COVID19 (disease); Disease or Syndrome
T73	PROC 2191 2194	PCR
#33	AnnotatorNotes T73	C0032520; Polymerase Chain Reaction; Molecular Biology Research Technique | C0201657; C-reactive protein measurement; Laboratory Procedure
T74	Speculated 2199 2211	clínicamente
T75	Spec_cue 2212 2222	sospechado
T76	DISO 2225 2237	tuberculosis
#34	AnnotatorNotes T76	C0041296; Tuberculosis; Disease or Syndrome | C0041327; Tuberculosis, Pulmonary; Disease or Syndrome
T77	DISO 2239 2250	hepatitis B
#35	AnnotatorNotes T77	C0019163; Hepatitis B; Disease or Syndrome
T78	PROC 2283 2288	HBsAg
#36	AnnotatorNotes T78	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T79	DISO 2291 2302	hepatitis C
#37	AnnotatorNotes T79	C0019196; Hepatitis C; Disease or Syndrome
T80	DISO 2305 2308	VIH
#38	AnnotatorNotes T80	C0458074; Human immunodeficiency virus (HIV) status; Finding
T81	PROC 2310 2329	anticuerpos VIH 1/2
T83	LIVB 2346 2378	Pacientes masculinos o femeninos
T84	PHYS 2383 2405	potencial reproductivo
T85	Spec_cue 2383 2392	potencial
T86	Speculated 2393 2405	reproductivo
T87	Neg_cue 2410 2412	no
T88	PROC 2443 2464	método anticonceptivo
#39	AnnotatorNotes T88	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T89	Negated 2443 2464	método anticonceptivo
T90	Negated 2465 2471	eficaz
T91	Duration 2511 2518	90 días
T93	PROC 2549 2560	monoterapia
#40	AnnotatorNotes T93	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T94	CHEM 2565 2575	durvalumab
#41	AnnotatorNotes T94	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T95	DISO 2581 2590	Toxicidad
#42	AnnotatorNotes T95	C0600688; Toxic effect; Injury or Poisoning
T96	Date 2602 2610	en curso
T97	Neg_cue 2612 2614	no
T98	Negated 2615 2623	resuelta
T99	Neg_cue 2629 2640	incapacidad
T100	PROC 2646 2672	reducir el corticosteroide
T101	Negated 2646 2672	reducir el corticosteroide
T102	Dose 2688 2697	</= 10 mg
T103	CHEM 2701 2711	prednisona
#43	AnnotatorNotes T103	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T104	Frequency 2712 2719	por día
T105	Duration 2739 2753	las 12 semanas
T108	PROC 2839 2863	Modificación de la dosis
T109	DISO 2867 2876	toxicidad
#45	AnnotatorNotes T109	C0600688; Toxic effect; Injury or Poisoning
T110	CHEM 2879 2882	TMG
T111	DISO 2901 2974	reacciones inmunológicas, relacionadas con la infusión y no inmunológicas
T112	PROC 2947 2955	infusión
#46	AnnotatorNotes T112	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T113	Neg_cue 2958 2960	no
T114	Negated 2961 2974	inmunológicas
T115	Date 12 16	2021
T23	PROC 975 992	estudio de origen
T116	PROC 1196 1219	estudio de origen de AZ
T50	PROC 1395 1426	protocolo del estudio de origen
T117	PROC 1595 1612	estudio de origen
T118	PROC 1830 1837	estudio
T119	PROC 1871 1888	estudio de origen
T71	DISO 2138 2147	Infección
T82	PROC 2497 2504	estudio
T106	CHEM 2788 2811	tratamiento del estudio
T107	PROC 2812 2831	régimen del estudio
T120	PROC 2979 2996	estudio de origen
T121	Route 2947 2955	infusión
